Fonte: Investigational New Drugs. Unidade: FMRP
Assuntos: EPIGÊNESE GENÉTICA, MEDULOBLASTOMA, ANTINEOPLÁSICOS
ABNT
ANDRADE, Augusto Faria et al. The DNA methyltransferase inhibitor zebularine exerts antitumor effects and reveal BATF2 as a poor prognostic marker for childhood medulloblastoma. Investigational New Drugs, v. 35, n. 1, p. 26-36, 2017Tradução . . Disponível em: https://doi.org/10.1007/s10637-016-0401-4. Acesso em: 31 ago. 2024.APA
Andrade, A. F., Borges, K. S., Suazo, V. K., Geron, L., Corrêa, C. A. P., Castro-Gamero, A. M., et al. (2017). The DNA methyltransferase inhibitor zebularine exerts antitumor effects and reveal BATF2 as a poor prognostic marker for childhood medulloblastoma. Investigational New Drugs, 35( 1), 26-36. doi:10.1007/s10637-016-0401-4NLM
Andrade AF, Borges KS, Suazo VK, Geron L, Corrêa CAP, Castro-Gamero AM, Vasconcelos EJR de, Oliveira RS de, Neder L, Yunes JA, Aguiar S dos S, Scrideli CA, Tone LG. The DNA methyltransferase inhibitor zebularine exerts antitumor effects and reveal BATF2 as a poor prognostic marker for childhood medulloblastoma [Internet]. Investigational New Drugs. 2017 ; 35( 1): 26-36.[citado 2024 ago. 31 ] Available from: https://doi.org/10.1007/s10637-016-0401-4Vancouver
Andrade AF, Borges KS, Suazo VK, Geron L, Corrêa CAP, Castro-Gamero AM, Vasconcelos EJR de, Oliveira RS de, Neder L, Yunes JA, Aguiar S dos S, Scrideli CA, Tone LG. The DNA methyltransferase inhibitor zebularine exerts antitumor effects and reveal BATF2 as a poor prognostic marker for childhood medulloblastoma [Internet]. Investigational New Drugs. 2017 ; 35( 1): 26-36.[citado 2024 ago. 31 ] Available from: https://doi.org/10.1007/s10637-016-0401-4